daglutril + losartan

**Daglutril + losartan** is a combination drug composed of daglutril and losartan. Daglutril is an inhibitor of both neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), which potentially leads to vasodilation by increasing the levels of natriuretic peptides and bradykinin while reducing the formation of angiotensin II, a potent vasoconstrictor. Losartan is a selective and competitive angiotensin II type 1 (AT1) receptor antagonist that blocks the effects of angiotensin II, resulting in vasodilation, reduced aldosterone release, and decreased blood pressure[2][4][6][8]. The rationale for combining these agents is to provide additive or synergistic antihypertensive, renal protective, and cardioprotective effects by targeting two distinct pathways in the regulation of vascular tone and renal function. Losartan is developed and manufactured by various pharmaceutical companies, while daglutril has been under clinical investigation and is not widely marketed or approved as a monotherapy.